Diagnostic utility of positron emission tomography-computed tomography and indications for 18F-Fluorodeoxyglucose and amyloid-tracers


Submitted: 1 August 2018
Accepted: 25 October 2018
Published: 9 November 2018
Abstract Views: 794
PDF: 307
HTML: 21
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Maria Lucia Calcagni Department of Diagnostic Imaging, Radiation Oncology and Hemathology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma; Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCSS, Roma, Italy.
  • Vanessa Feudo Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCSS, Roma, Italy.
  • Elizabeth Katherine Anna Triumbari Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCSS, Roma, Italy.
Positron emission tomography-computed tomography (PET-CT) is a nuclear medicine imaging technique widely used in oncology, cardiology and neurology where it’is becoming of great interest especially because of its role in the diagnosis and differential diagnosis between several pathological conditions involving the nervous system. In neurodegenerative diseases, the most used PET-CT radiopharmaceuticals are 18Fluoro-Fluorodeoxyglucose (18FFDG), a glucose analogue that is able to identify abnormalities of cerebral glucose metabolism, and amyloid-tracers (11C-PiB, 18F-Florbetapir, 18F-Flutemetamol, 18F-Florbetaben) that are able to detect presence of amyloid plaques. Depending on the specific characteristic of tracers and patient’s disease, the examination has dedicated appropriate indications that are illustrated in this article. PET-CT, with its several tracers, is an accurate tool in evaluating neurodegenerative diseases. 18F-FDG is considered a hallmark of the stage of the disease. Glucose hypometabolism in specific cerebral areas allows distinguishing different degenerative diseases. Amyloid tracers are considered the hallmark of the state of the disease. The uptake of PET-amyloids tracers reflects the cortical regional density of amyloid plaques.

Calcagni, M. L., Feudo, V., & Triumbari, E. K. A. (2018). Diagnostic utility of positron emission tomography-computed tomography and indications for 18F-Fluorodeoxyglucose and amyloid-tracers. Geriatric Care, 4(3). https://doi.org/10.4081/gc.2018.7729

Downloads

Download data is not yet available.

Citations